Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Intra-Arterial Injection for Chronic Subdural Hematoma (CHAI)
NCT06510582Phase 1Completed
- Sponsor
- Cooper University Health Care
- Start
- Jun 2024
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of bevacizumab in chronic subdural hematoma (CSDH) (2 arms), sponsored by Cooper University Health Care. Primary endpoint: Number of Participants with Serious Adverse Events at 3 months. Started Jun 2024; status: completed.
02
Drugs
bevacizumab
03
Conditions
chronic subdural hematoma (CSDH)
Beyond the preview
Go deeper on NCT06510582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06510582.